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Endocrine disruptors (EDs) are exogenous
compounds that have the potential to inter-
fere with hormonal regulations and the nor-
mal endocrine system and consequently
cause health effects in animals and humans
(U.S. Environmental Protection Agency
2000). EDs include environmental persistent
organohalogens, pesticides, and industrial
chemicals such as some plasticizers and sur-
factants. The involvement of EDs in disrup-
tion of development, reproduction, the
immune system, and the neural system has
been supported in a wide range of fish and
animal species, whereas for human beings
the ED hypothesis is still controversial
(Bonefeld-Jorgensen 2004; Bonefeld-
Jorgensen and Ayotte 2003; Owens and
Koeter 2003; vom Saal and Hughes 2005).
Most EDs are synthetic compounds, some of
which were designed to act as estrogens (e.g.,
oral contraceptives), whereas many were
designed for other purposes and accidentally
possessed estrogenic activity, such as plasti-
cizers (Krishnan et al. 1993; Soto et al.
1991). Naturally occurring xenoestrogens in
the environment include phytoestrogens
produced by plants reported to have
pleiotropic effects, including antioxidative
and apoptotic activity, inhibitors of kinases,
and suggested anticancer actions on prostate
and breast carcinomas (Basly and Lavier
2005; Mueller 2002; Sirtori et al. 2005).
Other EDs such as the pesticides vinclozolin,
procymidone, and p,p´-dichlorodiphenyl-
dichloroethene (DDE) possess in vitro and
in vivo androgenic actions and can affect
male reproduction in animals (Gray 1998).
Bisphenol A (BPA) and BPA dimeth-
acrylate (BPA-DM) are monomers used
largely in polycarbonate plastic and poly-
styrene resins and as dental sealants.
Halogenated derivatives of BPA, such as
tetrabromobisphenol A (TBBPA), are widely
used as ﬂame-retardants for building mater-
ial, paints, plastic products including epoxy
resin, electronic circuit boards, and other
electronic equipments. Depolymerization of
these products results in BPA and its deriva-
tives, which leach into foods (Brotons et al.
1995), into infant formula from plastic bot-
tles (Biles et al. 1999), into saliva of patients
treated with dental sealants (Olea et al.
1996; Pulgar et al. 2000), and in fresh food
at the microgram to milligram per kilogram
level (Vivacqua et al. 2003). BPA and
TBBPA have been detected in the concentra-
tion range of 0.1–10 ppb in human blood,
urine, and fetal tissues, and related BPA levels
in blood and fat tissues have also been
reported (Ikezuki et al. 2002; Schonfelder
et al. 2002; Thomsen et al. 2001; vom Saal
and Hughes 2005).
Alkylphenol ethoxylates (APEs) are
widely used surfactants and detergents in
domestic and industrial products and are
commonly found in wastewater. In sewage
treatment plant efﬂuents, APEs are degraded
to the more resistant alkylphenols such as
4-n-nonylphenol (nNP) and 4-n-octylphenol
(nOP). Data from studies across many
regions of the world have shown signiﬁcant
levels in samples of every environmental
compartment examined, including ﬁsh mus-
cle tissue (Ying et al. 2002), and they are gen-
erally ubiquitous in food as well (Guenther
et al. 2002).
The sex steroid receptors such as the
estrogen receptors (ER) α and ERβ and the
androgen receptor (AR) belong to the
nuclear receptor family and are ligand-
dependent transcription factors (Bjornstrom
and Sjoberg 2005; Schwabe and Teichmann
2004; Verrijdt et al. 2003). The genomic-
mediated pathway of EDs via ER and AR
includes steps such as binding of ligand to
receptor, translocation into nucleus, and
binding of the receptor–ligand complex to a
speciﬁc DNA response element causing gene
expression. 
Several years ago BPA, BPA-DM, nNP,
and nOP were reported to elicit estrogenic
activity (Andersen et al. 1999; Krishnan et al.
1993; Soto et al. 1991; Steinmetz et al. 1998;
White et al. 1994). Since then, numerous
studies have been carried out to assess the
endocrine disruption potentials of these
industrial compounds in vitro and in vivo
(Alonso-Magdalena et al. 2006; Choi and
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BACKGROUND: An array of environmental compounds is known to possess endocrine disruption
(ED) potentials. Bisphenol A (BPA) and bisphenol A dimethacrylate (BPA-DM) are monomers used
to a high extent in the plastic industry and as dental sealants. Alkylphenols such as 4-n-nonylphenol
(nNP) and 4-n-octylphenol (nOP) are widely used as surfactants.
OBJECTIVES: We investigated the effect in vitro of these four compounds on four key cell mecha-
nisms including transactivation of a) the human estrogen receptor (ER), b) the human androgen
receptor (AR), c) the aryl hydrocarbon receptor (AhR), and d) aromatase activity.
RESULTS: All four compounds inhibited aromatase activity and were agonists and antagonists of ER
and AR, respectively. nNP increased AhR activity concentration-dependently and further increased
the 2,3,7,8-tetrachlorodibenzo-p-dioxin AhR action. nOP caused dual responses with a weak
increased and a decreased AhR activity at lower (10–8 M) and higher concentrations (10–5–10–4 M),
respectively. AhR activity was inhibited with BPA (10–5–10–4 M) and weakly increased with BPA-
DM (10–5 M), respectively. nNP showed the highest relative potency (REP) compared with the
respective controls in the ER, AhR, and aromatase assays, whereas similar REP was observed for the
four chemicals in the AR assay.
CONCLUSION: Our in vitro data clearly indicate that the four industrial compounds have ED poten-
tials and that the effects can be mediated via several cellular pathways, including the two sex steroid
hormone receptors (ER and AR), aromatase activity converting testosterone to estrogen, and AhR;
AhR is involved in syntheses of steroids and metabolism of steroids and xenobiotic compounds.
KEYWORDS: androgenic, aromatase, BPA, BPA-DM, endocrine disruption, estrogenic, nNP, nOP,
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2005; Gutendorf and Westendorf 2001;
Kazeto et al. 2004; Mosconi et al. 2002;
Olsen et al. 2003; Rivas et al. 2002; Safe
et al. 2002; Sonnenschein and Soto 1998;
vom Saal and Hughes 2005; Williams et al.
2001). Many studies have focused on the
estrogenic activities of the compounds
in vitro by their potential to affect cell prolif-
eration (E-SCREEN) or ER transactivation
in human or yeast cells (e.g., Andersen et al.
1999; Legler et al. 2002; Van den Belt et al.
2004; Vivacqua et al. 2003; Wilson et al.
2004) or the binding capacity to steroid
receptors (Scippo et al. 2004). In animals,
the rodent uterotrophic bioassays have veri-
fied the estrogenic effects of BPA and nNP
(Owens and Koeter 2003), and developmen-
tal studies have revealed toxic effects of BPA-
DM on the reproductive system in mice
(Darmani and Al-Hiyasat 2004) and of nOP
in sows (Bogh et al. 2001).
Antagonistic effects on AR in vitro of
BPA, nNP, and nOP have previously been
reported (Lee et al. 2003; Paris et al. 2002;
Roy et al. 2004; Sultan et al. 2001; Xu et al.
2005). Neonatal exposure to BPA and nOP
affected development of the male reproduc-
tive system (Nagel et al. 1999) and plasma
testosterone in infant rats (Williams et al.
2001), whereas BPA was reported to have no
antiandrogenic effects on adult rats in the
Hersberger assay (Nishino et al. 2006).
An androgen:estrogen balance disturbed
by estrogenic compounds was suggested to
inﬂuence premature activation of spermato-
genesis in humans (Kula et al. 1996), being
consistent with the ability of BPA and nOP
to advance the onset of pubertal spermatoge-
nesis in rats (Atanassova et al. 2000). The
androgen:estrogen ratio is among other
things determined by aromatase (CYP19)
activity that is responsible for the irreversible
estrogen biosynthesis from androgens (Jones
et al. 2006; Seralini and Moslemi 2001;
Simpson et al. 2002). Depressed ovarian aro-
matase activity in the red mullet was suggested
to be caused by nNP and nOP (Martin-
Skilton et al. 2006), whereas increased CYP19
gene expression was reported in nNP-exposed
zebraﬁsh (Kazeto et al. 2004), and nNP- or
BPA-exposed medaka fish liver (Min et al.
2003). In rats, a decreased serum 17β-estradiol
(E2) and aromatase mRNA level in Leydig
cells was interpreted to play a role in inhibited
testicular steroidogenesis by BPA (Akingbemi
et al. 2004). Interestingly, although no effect
of BPA was observed on CYP19 mRNA levels
in human placental JEG-3 cells, a time- and
concentration-dependent modulation of the
aromatase activity was reported suggesting an
interaction between the enzyme and BPA
(Nativelle-Serpentini et al. 2003). In sum-
mary, effects on aromatase activity caused by
the alkylphenols and BPA have been reported
in ﬁsh, rodent, and human cell studies.
Many EDs elicit multiple mechanisms of
action; and apart from their cell and tissue-
specific ER and AR agonist or antagonist
activities, the involvement of other receptors
such as the aryl hydrocarbon receptor (AhR)
must be considered as well (Safe et al. 2002).
The AhR is a transcription factor that medi-
ates the effects of polyaromatic hydrocarbons,
dioxins such as 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), polychlorinated biphenyls
(PCBs) and other EDs such as certain pesti-
cides (Fujii-Kuriyama and Mimura 2005;
Long et al. 2003, 2006). As a heterodimer
with AhR-nuclear-translocator (Arnt), AhR
regulates the inducible expression of CYP1
and other CYP families and plays a crucial
role in xenobiotic metabolism, teratogenesis
(Thomae et al. 2006) and immune suppres-
sion (Novosad et al. 2002). In addition, stud-
ies with AhR-null female mice have shown
that AhR plays a key role in female reproduc-
tion by activating ovarian CYP19 gene tran-
scription (Baba et al. 2005). The potential of
BPA and alkylphenols to affect the role of
AhR is demonstrated by the following studies:
Low-dose in utero exposure of mice embryos
showed increased AhR mRNA expression in
brain, testes, and ovaries (Nishizawa et al.
2005b). BPA also up-regulated the mRNA
level of the AhR repressor (AhRR) and Arnt
in mid- and late-stage mice embryos, disrupt-
ing the expression of AhR and related factors
and xenobiotic metabolizing enzymes
(Nishizawa et al. 2005a). In mice Hepa-1c1c7
cells, nNP suppressed CYP1A1 expression by
antagonizing the dioxin-responsive element
(DRE) binding of nuclear AhR (Jeong et al.
2001). In parallel with E2, an estrogenic effect
of nNP was observed in marine ﬁsh, Gobious
niger, and the P4501A1 inhibition by nNP
was mediated through activation of the AhRR
(Maradonna et al. 2004). Also, in Atlantic
salmon nNP was suggested to have an impact
on the metabolism of endogenous and exoge-
nous substrates by modulation of hepatic
CYP1A1 via AhR (Meucci and Arukwe
2006). In summary, BPA and nNP are both
able to affect AhR action in cell cultures, in
murine fetuses, and/or in ﬁsh.
The aim of the present study was to
analyze the relative ED potencies of BPA,
BPA-DM, nNP, and nOP (Figure 1) in four
key in vitro bioassays for ED effects includ-
ing ER, AR, and AhR transactivation and
aromatase activity. 
Materials and Methods
Materials. BPA was obtained from Sigma-
Aldrich Co. (Birmingham, UK). BPA-DM
was purchased from Aldrich Chemical Co.
(St. Louis, MO, USA). nNP and nOP were
purchased from Lancaster Synthesis Ltd.
(Birmingham, UK) and Aldrich Chemical
Co., respectively. The four chemicals (purity
≥ 98%), and TCDD, 98% (Cambridge
Isotopes Laboratories Inc., Andover, MA,
USA) were dissolved in dimethyl sulfoxide
(DMSO) (BDH Laboratory Supplies, Pool,
UK). The E2 (Sigma, St. Louis, MO, USA)
was dissolved in 96% ethanol (extra pure;
Merck, Darmstadt Germany). Luciferin
and fluorescamine were from Amersham
Pharmacia Biotech (Piscataway, NJ, USA)
and Molecular Probes (Eugene, OR, USA),
Bonefeld-Jørgensen et al.
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Figure 1. Structures of the chemicals used in the present study. respectively, and bovine serum albumin
from Promega (Madison WI, USA); [1β-
3H]Androst-4-ene-3,17-dione was from
PerkinElmer (Boston, MA, USA), and both
4-androstene-3,17-dione (4-AD) and 4-
androsten-4-ol-3,17-dione (4-AOD) were
from Sigma Aldrich (Milwaukee, WI, USA).
Methyltrienolone (R1881) was purchased
from Mikromol Gmbh (Luckenwalde,
Germany). The structures of the test chemi-
cals are shown in Figure 1.
ER-activated luciferase expression assay.
We used the stable transfected MVLN cell
line, derived from the human breast adeno-
carcinoma MCF-7 cell line (Pons et al.
1990), to assess effects on ER–luciferase
transactivation as described by Bonefeld-
Jorgensen et al. (2005). The luciferase data
were corrected to cell protein, and the results
are given as relative light unit (RLU)/micro-
gram protein. Each compound was tested in
triplicate in at least three independent assays
alone and as co-treatment with 25 µM E2
[40% of the effect concentration (EC40) of
E2]. An E2 dose–response control (0.05–500
pM E2) was performed in parallel each analy-
sis day as described (Bonefeld-Jorgensen et al.
2005). The maximal (EC100) and half maxi-
mal (EC50) effective concentrations of E2
were 150 pM and 33 pM, respectively. 
Aromatase activity. We performed the
assay protocol as described by Drenth et al.
(1998), with minor modifications. Human
JEG-3 choriocarcinoma cells (no. HTB-36;
ATCC, Manassas, VA, USA) were main-
tained in minimum essential medium
(Invitrogen, Life Technologies, Glasgow, UK)
supplemented with 10% fetal calf serum,
2 mM L-glutamine, 64 mg/L garamycin, and
1 mM sodium pyruvate (Gibco BRL, Life
Technology, Gaithersburg, MD, USA). Cells
were seeded in 24-well culture plates (Nunc) at
4 × 104 cells/well in 1 mL culture medium for
2 days (∼ 50% confluence). Serum-free
medium ± test compound and/or control were
added (maximum 0.1% DMSO) and incu-
bated (37°C, 5% CO2/95% O2) for 18 hr
(∼ 90% conﬂuence), and then medium was
removed, cells were washed with phosphate-
buffered saline (PBS), and 0.5 mL serum-free
medium containing 0.2 µCi [1β-3H]androst-
4-ene-3,17-dione and 10 nM unlabeled 4-AD,
corresponding to the KM value of the enzyme,
was added. After 2 hr of incubation, the arom-
atization was terminated by placing the 24-
well plates on ice. We extracted 200 µL of the
culture medium with CHCL3, and treated
100 µL of the aqueous phase with 100 µL dex-
tran-charcoal in PBS (5%) (Sigma Aldrich).
Finally, we mixed 150 µL of the water phase
with 4 mL Hionic Fluor (Packard BioScience,
Groningen, the Netherlands) in a 6-mL vial
for scintillation (Packard BioScience) and
assayed for radioactivity (Packard Liquid
Scintillation Analyzer, model Tri-carb 2200;
Packard Instrument, Meriden, CT, USA).
The determined aromatase activity was sub-
tracted from background level (data from
wells with medium only), corrected to cell
protein concentration, and related to the sol-
vent control (0.1% DMSO). The protein
was determined on cell lyses with 0.5 mL
0.1 M NaOH by the modiﬁed Lowry protein
assay reagent (Pierce, Rockford, IL, USA)
according to the manufacturer’s manual. In
parallel, the 4-AOD was used as an aromatase
inhibitor control at 10 µM (EC100) and
6 nM (EC50). Each compound was tested at
10–9, 10–8, 10–7, 10–6, 10–5, and 10–4 M in
triplicate in at least three independent assays.
In each assay, all data were related to the pos-
itive control (substrate; 4-AD), which were
set to 100%. 
AhR-CALUX. The stable transfected
mouse hepatoma cell line Hepa1.12cR carry-
ing the pGudLuc1.1 AhR-luciferase reporter
gene was kindly provided by M.S. Denison
(University of California, Davis, CA, USA).
The AhR transactivation of luciferase (AhR-
CALUX) was carried out as described by
Long et al. (2003, 2006). The data are given
as RLU/microgram cell protein. Each com-
pound was tested in at least three indepen-
dent assays in quadruplicate. The mean of the
solvent control (0.1% DMSO) (basal activ-
ity) was set to 1, to which the activity of test
compounds was related. Results are reported
as mean ± SD. 
Cell cytotoxicity. Cell cytotoxicity tests for
the ER, AhR-CALUX, and aromatase assays
were performed according to the CellTiter 96
Non-Radioactive Cell Proliferation assay
from Promega (Madison, WI, USA) and
cytotoxicity detection kit (LDH) from Roche
(Mannheim, Germany) as described by
Bonefeld-Jorgensen et al. (2005) and Long
et al. (2003).
Statistical analyses for aromatase-, ER-,
and AhR-transactivation analyses. The statis-
tical analysis was performed in SPSS 10.0
(SPSS Inc., Chicago, IL). Because of inequal-
ity of variance and relatively few data points
per concentration, nonparametric statistics
was performed. We used the Kruskal-Wallis
test to compare differences between different
concentrations, and the Jonckheere-Tepstra
test to analyze for a linear trend between con-
centrations and response. If one or both tests
showed a signiﬁcant difference (p ≤ 0.05), we
used the Mann-Whitney test to compare the
difference between each test concentration
and the respective control.
We performed dose–response analysis in
Sigma Plot 8.0 (SPSS) by fitting the curves
to the four (ER) and three (aromatase, AhR)
“parameter sigmoid curve” ﬁt, and calculated
EC100, EC50, IC100, or IC50 for each test
compound.
AR-reporter gene assay. We tested AR
transactivation in a luciferase reporter assay.
Chinese hamster ovary (CHO) cells were
transiently transfected with the expression
vector pSVAR0 (human AR) and the
MMTV-LUC reporter plasmid as described
by Vinggaard et al. (2002), except that most
pipetting procedures were performed using a
Biomek2000 laboratory robot (Beckman
Coulter, Fullerton, CA, USA) and that 0.1
nM R1881 was used as the AR agonist. Each
test compound was tested at concentrations
of 0.15, 0.3, 1.3, 2.5, 5, 10, 20, and 40 ×
10–6 M in three independent assays as tripli-
cates, and within each assay all data were
related to 0.1 nM R1881, which was set to
100%. Using the SigmaStat program, we
performed analysis of variance, and if data
were statistically significant followed with a
Dunnett’s test (p < 0.05). Dose–response
analysis was performed in Sigma Plot ﬁtting
the curves to the “four parameter logistic
curve” ﬁt, and IC50 (half maximal inhibitory
concentration) was calculated for each test
compound. We determined cytotoxicity in
parallel by transfecting cells with a plasmid
(pSVAR13) encoding for a constitutively
active AR, which lacks the ligand-binding
domain (Vinggaard et al. 2002). These
experiments were designed exactly as was the
AR reporter gene assay except that the ratio
between pSVAR13 and MMTV-LUC was
2:100.
Results
Effects on ER transactivity. BPA and BPA-DM
elicited ER-mediated dose–response luciferase
activity in the concentration range of 10–8 to 5
× 10–5 M, with the maximum response being
approximately 75% of the natural ligand E2-
induced maximum response. The EC50 values
were 3.9 µM for BPA and 4.8 µM for BPA-
DM. (Figure 2, Table 1). Co-treatment of
MVLN cells with 25 pM E2 (EC40) and each
of the two compounds showed at 5 µM and 10
µM a further increased estrogenic effect above
the E2 EC40 control, whereas the significant
decreased response at 50 µM might be the
beginning of cell cytotoxicity (Figure 2B).
Although lower maximum induction was
observed, the alkylphenols nNP and nOP
alone also elicited a clearly significant estro-
genic response in the concentration range of
10–8 M to 10–5 M and 10–6 M to 10–5 M,
respectively, with EC50 values of 8.9 µM and
4.9 µM, respectively (Figure 2, Table 1). We
observed further increase of the 25 pM E2-
induced activity level for nNP and nOP at 5 ×
10–6 and 5 × 10–6–10–5 M, respectively
(Figure 2B); cytotoxicity was observed at 25
and 50 µM, respectively (Table 1).
Effects on AR transactivity. BPA, BPA-
DM, nNP, and nOP elicited a significantly
antiandrogenic effect on the R1881-induced
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IC50 values of 1.0, 2.3, 14.1, and 1.1 µM,
respectively, and a maximum inhibition (MI)
of 90, 89, 56, and 92%, respectively. We
determined cytotoxicity for BPA, BPA-DM,
and nNP at concentrations > 40 µM and for
nOP at concentrations > 20 µM (Figure 3
and Table 1). 
Aromatase activity. The inhibitor control
4-AOD caused an aromatase inhibition in the
concentration range of 10–9 M to 10–3 M, with
an IC50 of 6 × 10–9 M and 100% inhibition
at 10–4 M (Table 1). BPA and BPA-DM
decreased the aromatase activity signiﬁcantly
at 10–4 M, with MI of 59% and 40%, respec-
tively. nNP and nOP decreased the aro-
matase activity in the range 10–9–10–5 M and
10–7–10–5 M, respectively, with MI at 10–5 M
of 71% and 47%, respectively. Cytotoxicity
was observed at 10–4 M for both nNP and
nOP (Table 1).
Effects on AhR transactivation. Effects on
AhR transactivation data are shown in Table
1 and Table 2. Decreased AhR activity was
observed for BPA alone and on co-treatment
with TCDD-EC50 at 5 × 10–5 to 10–4 M and
10–4 M, respectively. BPA-DM alone weakly
but signiﬁcantly increased the CALUX activ-
ity at 10–5 M. Although weak compared with
TCDD, nNP alone elicited significant
increased (∼ 4-fold) dose–response AhR-
CALUX activity in the range of 5 × 10–8 M
to 10–4 M, with an EC50 of 24 µM.
Moreover, nNP further increased and
decreased the TCDD-induced AhR activity
at 2.5–5 × 10–5 M and 10–4 M, respectively.
For nOP alone, weak increased AhR-CALUX
activity was observed at 10–8–2.5 × 10–8 M,
whereas a decrease was observed at 5 × 10–5
M and 10–4 M. At 10–4 M, nOP decreased
TCDD-induced activity by 60%. None of
the compounds elicited any toxicity in
Hepa1.1 2cR cells at the tested concentration
range. Rather, each of the compounds caused
a significantly increased cell proliferation at
10–4 M. However, we cannot exclude that
the decreased CALUX activity observed at
10–4 M for all compounds, except nNP
alone, might be a response due to beginning
cytotoxicity.
Discussion
In the present study we demonstrated that
BPA, BPA-DM, nNP, and nOP elicited an
impact on most of the selected end points:
ER, AR, AhR, and aromatase activity.
Estrogenicity was observed for the four com-
pounds where BPA and nNP showed the
highest relative potency compared with E2,
supporting previously reported in vitro and
in vivo data. The four chemicals also antago-
nized AR transactivation in a concentration-
dependent manner, with IC50 values in the
order BPA ≤ nOP ≤ BPA-DM < nNP. In
addition, all four chemicals inhibited the aro-
matase activity in JEG-3 cells. Furthermore,
nNP activated AhR in a concentration-
dependent manner; BPA-DM activated AhR
at 10–5 M only, whereas BPA inhibited the
AhR action at 5 × 10–5 to 10–4 M, and nOP
elicited a weakly induced and a decreased
AhR activity at lower and higher concentra-
tions, respectively. Thus our in vitro data
indicate that the four industrial chemicals
have the potential to affect several cellular
pathway systems, including gene expressions
regulated via the steroid receptors ER and
AR, the conversion of testosterone into estro-
gen by aromatase, and the function of AhR,
involved in syntheses of steroids such as estro-
gens and metabolism of steroids and xeno-
biotic compounds. 
MVLN cells, derived from MCF-7 cells
(Pons et al. 1990), express both ERα and
ERβ (Gaido et al. 1998; Grunfeld and
Bonefeld-Jorgensen 2004; Hofmeister and
Bonefeld-Jorgensen 2004) that can bind the
ER response element vitellogenin, vit-tk, in
Bonefeld-Jørgensen et al.
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Figure 2. Dose–response ER transactivation of E2 and the four test chemicals. (A) The MVLN cells were
exposed to E2 in the concentration range of 0.05–500 pM and to the test chemicals at 10–8–10–4 M for 24 hr.
Solvent control was set to 100%. E2 EC100 and EC50 as well as EC50 for each of the test chemicals were
determined by Sigma Plot 8.0. (B) Agonistic and antagonistic ER activity of test chemicals BPA, BPA-DM,
nNP, and nOP. The chemicals were tested alone or on co-exposure with 25 pM E2, which was set to 1.
Mean values are shown (n ≥ 3). 
*Signiﬁcantly different from the respective solvent controls (cells + 0.1% DMSO; 25 pM E2 + 0.1% DMSO). 
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DMSO (M)front of the luciferase gene (Gruber et al.
2004). Thus the estrogenicity demonstrated
for the four tested compounds in our analyses
is mediated by transactivation of ERα and/or
ERβ. Moreover, based on previous reports
including E-SCREEN, ER transactivation,
binding assays to the two ER subtypes, and
effects observed with the ER antagonists ICI
182,780 and tamoxifen (Gutendorf and
Westendorf 2001; Scippo et al. 2004;
Vivacqua et al. 2003; Wilson et al. 2004), we
can conclude that the estrogenic potential of
these four compounds is accomplished
through the ERs. However, we cannot
exclude that other cellular mechanisms are
involved, such as activation of the transcrip-
tion factor cAMP-responsive element binding
protein via binding to nonclassical membrane
ERs (Quesada et al. 2002). In addition, BPA
and nNP effects were exerted predominantly
by the parent compounds and not by their
metabolites (Legler et al. 2002). 
We observed an antagonistic effect on
R1881-induced AR transactivition of the four
tested chemicals. To our knowledge, the AR
antagonism of BPA-DM has not previously
been reported. As we performed the present
study, another study using transiently trans-
fected [human AR (hAR) and MMTV-CAT]
Africa monkey kidney CV-1 cells reported an
antagonizing effect on AR by BPA, nNP, and
nOP with similar IC50 values, except that
nOP had an IC50 approximately 100 times
higher (97.1 µM) (Xu et al. 2005) than ours.
In contrast, in a recently established stably
transfected CHO-AR-LUC cell line, only
BPA but not nNP and nOP elicited anti-AR
effects (Roy et al. 2004); similarly, BPA but
not nNP antagonized AR action in stable
transfected (hAR and MMTV-luciferase) PC-
3 prostate cells (Paris et al. 2002; Sultan et al.
2001). Our AR antagonistic data for BPA and
nNP are consistent with results obtained in
yeast (Lee et al. 2003) and transient trans-
fected (hAR and ARE2-luciferase) NIH3T3
cells (Kitamura et al. 2005). In contrast, BPA
showed no effect on AR action in transient
transfected (hAR and MMTV-luciferase)
human hepatoma HepG2 cells (Gaido et al.
2000). Whole cell binding assays showed that
BPA has the potential of binding to the AR
(Paris et al. 2002). We suggest that the anti-
AR action observed in the present study for
BPA, BPA-DM, nNP, and nOP indicates that
the chemicals have the ability to bind the AR
and thus compete with endogenous androgens
for binding and regulating AR-dependent gene
expression. However, indirect interference
with other transcriptional factors involved in
AR transactivation may also play a role. The
discrepancy between the reported AR effects of
the compounds might be caused by different
sensitivities of the various assays, differences in
co-factors in the different cell lines, and/or the
use of different AR response elements
(Sommer and Haendler 2003; Verrijdt et al.
2003). However, it is important to clarify the
cause(s) of the discrepancies in the use of AR-
reporter analyses to assess the potential actions
of chemicals on androgenic processes in vivo.
In the synthesis of steroid hormones from
cholesterol, the aromatase enzyme is pivotal
by its irreversible conversion of androgens to
estrogens (Simpson et al. 2002). Aromatase,
which is located in the endoplasmic reticu-
lum membrane, is expressed in several tissues
and cell types in humans, including adipose
tissue, various sites of the brain, and testicular
Leydig cells in males (Jones et al. 2006).
Aromatase activity and endogenous estrogens
(and ERs) are important in male reproduc-
tion (Carreau et al. 2006). In rat Leydig cells,
BPA inhibited testicular steroidogenesis by a
decrease in 17α-hydroxylase/17-20 lyase and
CYP19 expression causing decreased testos-
terone and E2 synthesis (Akingbemi et al.
2004). After 18-hr exposure of JEG-3 cells to
BPA, BPA-DM, nNP, or nOP, we observed
a signiﬁcant inhibition of aromatase activity.
To our knowledge, this is the first report
showing BPA-DM, nNP, and nOP effects on
aromatase activity in mammalian cells. nNP
and, to lesser extent nOP, caused a dose-
dependent inhibition of aromatase activity in
the range of 10–9–10–5M. Our data are sup-
ported by an earlier report examining BPA in
JEG-3 cells, in which a signiﬁcant effect was
observed on aromatase activity but not on
gene expression (Nativelle-Serpentini et al.
2003). Given the observation that short
(2 hr) exposure increased and long (18 hr)
exposure decreased aromatase activity, and
that parallel transfections with CYP19 cDNA
elicited similar effects, Nativelle-Serpentini
et al. (2003) concluded that the xenobiotics
acted at the aromatase protein level. In sum-
mary, the tested plasticizers seem to have the
potential to affect the aromatase activity and
thus the synthesis of estrogens in mammals as
well as in fish (Kazeto et al. 2004; Martin-
Skilton et al. 2006; Min et al. 2003).
The present study suggests that BPA,
BPA-DM, nNP, and nOP have the potential
for indirect AhR-mediated actions on xeno-
biotic metabolism, steroid synthesis, and
metabolism. This is the first report, to our
knowledge, showing the ability of BPA-DM
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Table 1. ER, AR, AhR, and aromatase characteristics of the four test chemicals alone. 
Assay LOEC MOEC Maximum %a REP EC50
b/IC50
c Cytotox (M)
ER
E2 1 × 10–11 1.5 × 10–10 — 1 3.3 × 10–11b —
BPA 1 × 10–7 1 × 10–5 —1   × 10–4 3.9 × 10–6b —
BPA-DM 5 × 10–6 1 × 10–5 —2   × 10–6 4.8 × 10–6b —
nNP 1 × 10–8 1 × 10–5 —1   × 10–3 8.9 × 10–6b 2.5 × 10–5
nOP 5 × 10–6 1 × 10–5 —2   × 10–6 4.9 × 10–6b 5.0 × 10–5
ARd
BPA 0.6 × 10–6 2 × 10–5 90 ND 1.0 × 10–6c > 4 × 10–5
BPA-DM 2.5 × 10–6 2 × 10–5 89 ND 2.3 × 10–6c > 4 × 10–5
nNP 2.5 × 10–6 2 × 10–5 56 ND 1.4 × 10–5c > 4 × 10–5
nOP 0.6 × 10–6 1 × 10–5 92 ND 1.1 × 10–6c > 2 × 10–5
Aromatased
4-AOD 1 × 10–9 1 × 10–4 100 1 6 × 10–9c —
BPA 1 × 10–4 1 × 10–4 59 1 × 10–5 — — 
BPA DM 1 × 10–4 1 × 10–4 40 1 × 10–5 ——
nNP 1 × 10–9 1 × 10–5 71 1 — 1 × 10–4
nOP 1 × 10–7 1 × 10–5 47 1 × 10–2 —1   × 10–4
AhR
TCDD 2 × 10–12 1 × 10–8 — 1 6.4 × 10–11b —
BPAd 5 × 10–5d 1 × 10–4d 54 — ND > 10–4
BPA-DM 1 × 10–5 1 × 10–5 —1   × 10–7 ND > 10–4
nNP 5 × 10–8 1 × 10–4 —4   × 10–5 2.4 × 10–5 > 10–4
nOP 1 × 10–8 2.5 × 10–8 —1   × 10–4 ND > 10–4
nOPd 5 × 10–5d 1 × 10–4d 46 — ND > 10–4
Abbreviations: —, no data; LOEC, lowest effect concentration in molar (M); MOEC, maximal effect concentration in molar
(M); ND, not determined; REP, relative potency. 
aMaximum down-regulation of the control inducer, which was set to 100% [0.1 nM R1881 (AR), 10 nM 4-AD (aromatase),
60 pM TCDD (AhR)]; REP-ER = LOECE2/LOECtest chemical; REP-aromatase = LOEC4-AOD/LOECtest compound. bEC50/cIC50: Molar
concentration which exert 50% increase/50% inhibition compared to the max response of their respective control,
respectively. dInhibited activity. 
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Figure 3. AR antagonism of the test chemicals on
co-exposure with R1881 in transient transfected
CHO-K1 cells. Cells were transiently transfected
with the AR expression pSVAR0 and the reporter
pMMTV-LUC vector. Bonefeld-Jørgensen et al.
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and nOP to affect the transactivation of AhR.
BPA and BPA-DM elicited in the 10–5 M
range weak antagonistic and agonistic AhR
effects, respectively. We observed a clear dose-
dependent AhR activation for nNP, although
it was weak compared with that for TCDD.
In previous in vitro studies, BPA and nNP
had no effects on their own, but antagonized
TCDD-induced CYP1A1 mRNA and
7-ethoxyresorufin-O-deethylase (EROD)
activity levels in Hepa-1c1c7 cells via interfer-
ence with AhR:DRE binding and/or transport
into the nucleus and/or the action of co-tran-
scription factors (Jeong et al. 2000, 2001).
Similarly to BPA and nNP, estradiol was
shown to antagonize AhR:TCDD-induced
CYP1A1 expression and EROD activity, and
weakly induce EROD activity via AhR not
involving ER (Jeong and Lee 1998). In vivo,
the endocrine disruption potential of BPA on
mice embryonic development was demon-
strated at very low doses (0.02 µg/kg/day)
(Nishizawa et al. 2005a, 2005b). 
We observed weak increased and
decreased AhR activity at lower (10–8 M)
and higher (10–6 M) nOP concentrations,
respectively, and nOP also induced ER activ-
ity at ∼ 10–6 M. We wonder whether this
estrogenic mimic of nOP can be explained
by the fact that the bifocal effects of estradiol
on AhR can either induce or antagonize AhR
function (Jeong and Lee 1998; Kharat and
Saatcioglu 1996). That nOP elicited AhR
agonism at lower concentrations and reduced
AhR transactivation at higher concentrations
might be attributed to inhibitory cross-talk
of AhR and ER. However, the speciﬁc mech-
anisms involved must be further studied.
The demonstration in AhR knock-out
mice that AhR is an important factor in
female reproduction by regulating the
expression of ovarian aromatase elucidates
the physiologic role of AhR and also suggests
AhR as a mediator of endocrine disruption
(Baba et al. 2005). Antiestrogenic actions
mediated via AhR are well described, in
which AhR:ligand inhibits ER binding to
ERE (Pocar et al. 2005) and increases pro-
teasomal degradation of ER (Wormke et al.
2003). A further perspective of AhR as a fac-
tor in ED is given by AhR’s estrogenic
potential in absence of estrogen via the ago-
nist-activated AhR:Arnt interaction, with
ERα and/or ERβ leading to transcriptional
activation of ER-regulated genes (Ohtake
et al. 2003). In addition, antiandrogenic
actions of TCDD have pointed out two pos-
sible mechanisms: blocking of AR-induced
gene expression and AhR–AR cross-talk pos-
sibly involving competition of co-regulators
(Barnes-Ellerbe et al. 2004; Jana et al. 1999).
Hypothetically, AhR might play a role in
regulating the cell ratio of androgens:estro-
gens via activation of CYP19, thereby affect-
ing male and female reproduction, affecting
estrogenic actions via ERs, inducing cell
metabolism via, for example, CYP1A, and
inhibiting AR functions.
In summary, our in vitro data demon-
strated that the four tested chemicals have the
potential to affect central endocrine pathways
through their capacity to affect the function of
the nuclear receptors ER, AR, AhR, and aro-
matase activity. BPA-related compounds and
alkylphenols have been found in human ﬂuids
in 0.1–10 nM (vom Saal and Hughes 2005)
and 0.4–13.9 ng/mL urine (Kawaguchi et al.
2004; Kuklenyik et al. 2003), respectively. In
this study, the lowest observed effect concen-
trations for the BPA phenols and the
alkylphenols were in the 100–1,000 nM and
10–1,000 nM ranges, respectively. Although
the effective concentrations in vitro for the
tested compounds were ≥ 1,000 times higher
than the level found in humans, their ability
to act via more than one mechanism might
enhance the biologic effect in the intact
organism, because the ﬁnal response will likely
be determined as a sum of the interactions of
all pathways implicated. Furthermore, because
most humans are exposed to several chemicals
simultaneously and some EDs have been
shown to act additively in vitro and in vivo
(Birkhoj et al. 2004; Nellemann et al. 2003;
Rajapakse et al. 2002), potential mixture
effects should also be taken into consideration
in the risk assessment. 
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